MedTrace Logo

Effect of Acute Cardiovascular Disease on Microbiome

NCT05456802 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-09-24

No results posted yet for this study

Summary

Atherosclerotic diseases such as coronary artery disease (CAD) and peripheral arterial disease (PAD) are the leading cause of morbidity and mortality in the industrialized world.

An interaction between the development of atherosclerotic diseases and the oral and enteral microbiome composition has already been demonstrated in the past. The microbiome is a double-edged sword which can convey protective and detrimental cardiovascular effects. While it can promote the development of atherosclerosis through the production of atherogenic metabolites such as trimethylamine N-oxide (TMAO) it can also generate a protective effect through the production of metabolites such as short chain fatty acids (SCFA). Preliminary data suggest that atherosclerotic disease itself can induce a dysbiosis of the microbiome.

Aim of this study is to determine the differences in coronary artery disease and peripheral arterial disease on the oral-enteral microbiome axis and downstream microbiome-dependent metabolites.

Conditions

Interventions

OTHER

Standard of care treatment

Standard of care treatment including percutaneous interventions was performed in all participants.

Sponsors & Collaborators

  • University Hospital, Essen

    lead OTHER

Principal Investigators

  • Christos Rammos, Prof. Dr. · University Clinic Essen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-12
Primary Completion
2024-02-01
Completion
2024-04-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05456802 on ClinicalTrials.gov